Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer

Trial Profile

Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top